EF Hutton Maintains Buy on FibroBiologics, Maintains $16 Price Target
Portfolio Pulse from Benzinga Newsdesk
EF Hutton analyst Jason Kolbert has reiterated a Buy rating for FibroBiologics (NASDAQ:FBLG) and maintained a price target of $16.
October 18, 2024 | 3:44 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
EF Hutton analyst Jason Kolbert has reiterated a Buy rating for FibroBiologics and maintained a price target of $16, indicating confidence in the company's future performance.
The reaffirmation of a Buy rating and a $16 price target by EF Hutton suggests a positive outlook for FibroBiologics. This could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100